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Abstract: (1) Background: In a previous study, we found that two phenotypes related to platelet
reactivity, measured with the PFA-100 system, were highly heritable. The aim of the present study
was to identify genetic determinants that influence the variability of these phenotypes: closure time of
collagen-ADP (Col-ADP) and of collagen-epinephrine (Col-Epi). (2) Methods: As part of the GAIT-2
(Genetic Analysis of Idiopathic Thrombophilia (2) Project, 935 individuals from 35 large Spanish
families were studied. A genome-wide association study (GWAS) with ≈ 10 M single nucleotide
polymorphisms (SNPs) was carried out with Col-ADP and Col-Epi phenotypes. (3) Results: The study
yielded significant genetic signals that mapped to the ABO locus. After adjusting both phenotypes for
the ABO genotype, these signals disappeared. After adjusting for von Willebrand factor (VWF) or for
coagulation factor VIII (FVIII), the significant signals disappeared totally for Col-Epi phenotype but
only partially for Col-ADP phenotype. (4) Conclusion: Our results suggest that the ABO locus exerts
the main genetic influence on PFA-100 phenotypes. However, while the effect of the ABO locus on
Col-Epi phenotype is mediated through VWF and/or FVIII, the effect of the ABO locus on Col-ADP
phenotype is partly produced through VWF and/or FVIII, and partly through other mechanisms.
Keywords: platelet reactivity; platelet function test; ABO blood-group system; von Willebrand factor;
factor VIII
1. Introduction
Platelet reactivity can be measured using a wide variety of laboratory functional tests. Such tests
are classified into two main types [1]: (1) tests based on platelet aggregation activated by agonists, in
platelet-rich plasma or in whole blood; (2) tests based on platelet adhesion under shear stress. Among
the second group of tests, the PFA-100 system (Siemens Healthcare Diagnostics, Marburg, Germany)
measures platelet function by simulating in vitro a vessel wall under shear stress. The vessel wall is
simulated by a membrane coated with collagen; it is coated also with ADP (cartridge collagen-ADP)
or with epinephrine (cartridge collagen-epinephrine) as platelet agonists. The membrane has a hole
through which the anticoagulated blood passes; the closure times (CTs) of this hole are inversely
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proportional to the functional capacity of platelets. The PFA-100 system was introduced in 1995
with the objective of measuring primary hemostasis in whole blood in vitro as a non-invasive and
more accurate method than the bleeding time in vivo [2,3]. Long CTs gave reliable measurements
of hemostatic deficiencies due to low levels of von Willebrand factor (VWF) or platelet functional
defects [2,4]. The use of PFA-100 was subsequently expanded to the assessment of the effect of platelet
hyperreactivity, as indicated by shortened CTs, on arterial and venous thrombotic risk [3,5–8]. Citrate
concentration, platelet count, hematocrit, white blood cell count, circadian rhythm and some dietary
elements can influence the CTs [3,9,10]. Age and sex do not have appreciable influence although slight
shortening of CTs has been described in neonates, in children and in elderly men [3,10,11]. Obviously,
VWF has an important influence on CTs, which correlates inversely with VWF levels [3,4,9,10]. Also,
the ABO blood group influences PFA-100 CTs, with O group individuals having longer CTs than those
of non-O groups [3,4,9,10,12,13]; this has been interpreted as an effect of the lower levels of VWF in
group O individuals [4,9,10]. Some authors have suggested that factor VIII (FVIII) has no impact on
the PFA-100 CTs [2,5], while others have found the contrary [14].
The GAIT-2 (Genetic Analysis of Idiopathic Thrombophilia (2) Project is a family-based genetic
study designed to identify new genetic markers of thrombotic risk [15]. Using the variance component
statistical method, the heritability of intermediate phenotypes that could play a role in thrombotic
risk was determined. In the GAIT-2 Project, two PFA-100 phenotypes were included as a measure of
platelet reactivity: CTs of collagen-ADP cartridge (Col-ADP) and of collagen-epinephrine cartridge
(Col-Epi). Both phenotypes showed a strong genetic component with a heritability of 0.45 for Col-ADP
and 0.52 for Col-Epi [16].
The objectives of the present study were: (1) to analyze the genetic correlations between
Col-ADP and Col-Epi phenotypes with each other and with other related phenotypes, and (2) to
perform a genome-wide association study (GWAS) to identify susceptibility loci for Col-ADP and
Col-Epi phenotypes.
2. Results and Discussion
2.1. Genetic Correlations of the PFA-100 Phenotypes
The genetic correlations of Col-ADP and Col-Epi with each other and with the VWF antigen,
coagulant FVIII and ABO genotype (considering dominant effect of allele O) are presented in Table 1.
Table 1. Genetic correlations among PFA phenotypes, von Willebrand factor, coagulation factor VIII
and ABO genotype.
Phenotype Col-Epi VWF FVIII ABO
Col-ADP ρ = 0.7917 (5.80 × 10−9) ρ = −0.7002 (1.02 × 10−10) ρ = −0.6209 (2.66 × 10−8) ρ = 0.5895 (7.01 × 10−9)
Col-Epi - ρ = −0.6342 (7.14 × 10−8) ρ = −0.5947 (3.97 × 10−7) ρ = 0.4477 (0.0003)
ρ = genetic correlation and p-value (in brackets); VWF = von Willebrand factor antigen; FVIII = coagulation factor
VIII activity; ABO = ABO genotype, considering dominant effect of allele O.
As expected, the genetic correlations of PFA-100 phenotypes with VWF and ABO blood group
were statistically significant. In addition, a significant correlation between the PFA-phenotypes and
FVIII was also observed. Unlike VWF, which has an important role in primary hemostasis, FVIII is
fundamental for coagulation. The mechanism by which the FVIII influences the PFA-100 CTs could be
partially explained by its close relationship with the VWF. Both factors circulate together, and their
levels are related. Moreover, genetic studies have demonstrated that there is a huge overlap between
genetic factors regulating FVIII and VWF [17,18].
2.2. GWAS of the PFA-100 Phenotypes
Manhattan plots of the GWAS on Col-ADP and Col-Epi phenotypes are shown in Figure 1.
Int. J. Mol. Sci. 2019, 20, 3221 3 of 13
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 3 of 12 
 
anhattan plots of the GWAS on Col-ADP and Col-Epi phenotypes are shown in Figure 1. 
 
Figure 1. Manhattan plots of the GWAS on two PFA-100 phenotypes: collagen-ADP and collagen 
epinephrine closure times. Dots correspond to SNPs organized by chromosomal order and position 
and the vertical axis shows the statistical significance expressed as −log10 of the p-values. The 
horizontal lines mark the 5 × 10−8 p-value threshold of genome-wide significance. 
For each phenotype, a signal on chromosome 9 at the ABO locus reached a genome-wide 
significance level (p-value < 5 × 10−8). Seventy single nucleotide polymorphisms (SNPs) were found 
to be associated with Col-ADP, with p-values up to 1.50 × 10−15. Of these 70 SNPs, 45 were associated 
also with Col-Epi but with less statistical significance: p-values up to 1.35 × 10−9. The complete list of 
these SNPs is described in Supplementary Table S1. For both Col-ADP and Col-Epi phenotypes, all 
significant SNPs were located within the ABO gene and in its adjacent intergenic region. 
To the best of our knowledge, our study is the first GWAS of PFA-100 phenotypes. Previous 
GWAS reports of platelet reactivity phenotypes were mainly based on aggregometry. Using GWAS 
and other genetic approaches, several SNPs have been found in association with platelet 
aggregometry phenotypes. These were located in different genes related to platelet functional 
receptors, regulators of cytoskeleton and signaling proteins. Among these genes, the following were 
described: MIR100HG, MME, PIP3-E, GLIS3, LDHAL6A, ANKS1B, PIK3CG, MAGI1, C8orf86, FGFR1, 
LPAR1, CACNB2, SLC39A12, RPP25, SCAMP5, BMPR1A (revisited in Bunimov et al. [19]), ANKRD26 
[20], pannexin [21], ADRA2 [22] and the most relevant PEAR-1 [22–24]. Notably, none of these genetic 
variants was found in the ABO locus. On the other hand, in our study, we did not find any of the 
SNPs previously reported to be associated with platelet aggregometry. To explain these different 
results, we should keep in mind that aggregometry, both in platelet-rich plasma and in whole blood, 
analyzes aggregation, that is, the platelet-platelet binding mediated by fibrinogen. In contrast, the 
Figure 1. Manhattan plots of the GWAS on two PFA-100 phenotypes: collagen-ADP and collagen
epinephrine closure times. Dots correspond to SNPs organized by chromosomal order and position and
the vertical axis shows the statistical significance expressed as −log10 of the p-values. The horizontal
lines mark the 5 × 10−8 p-value threshold of genome-wide significance.
For each phenotype, a signal on chromosome 9 at the ABO locus reached a genome-wide
significance level (p-value < 5 × 10−8). Seventy single nucleotide polymorphisms (SNPs) were found
to be associated with Col-ADP, with p-values up to 1.50 × 10−15. Of these 70 SNPs, 45 were associated
also with Col-Epi but with less statistical significance: p-values up to 1.35 × 10−9. The complete list of
these SNPs is described in Supplementary Table S1. For both Col-ADP and Col-Epi phenotypes, all
significant SNPs were located within the ABO gene and in its adjacent intergenic region.
To the best of our knowledge, our study is the first GWAS of PFA-100 phenotypes. Previous
GWAS reports of platelet reactivity phenotypes were mainly based on aggregometry. Using GWAS
and other genetic approaches, several SNPs have been found in association with platelet aggregometry
phenotypes. These were located in different genes related to platelet functional receptors, regulators of
cytoskeleton and signaling proteins. Among these genes, the following were described: MIR100HG,
MME, PIP3-E, GLIS3, LDHAL6A, ANKS1B, PIK3CG, MAGI1, C8orf86, FGFR1, LPAR1, CACNB2,
SLC39A12, RPP25, SCAMP5, BMPR1A (revisited in Bunimov et al. [19]), ANKRD26 [20], pannexin [21],
ADRA2 [22] and the most relevant PEAR-1 [22–24]. Notably, none of these genetic variants was found
in the ABO locus. On the other hand, in our study, we did not find any of the SNPs previously reported
to be associated with platelet aggregometry. To explain these different results, we should keep in mind
that aggregometry, both in platelet-rich plasma and in whole blood, analyzes aggregation, that is,
the platelet-platelet binding mediated by fibrinogen. In contrast, the PFA-100 test basically analyzes
adhesion under shear stress, which depends mainly on binding with VWF [2,10].
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Nineteen of the SNPs that we found in the ABO locus have been previously reported in
relation to thrombotic-related conditions (Table 2): Venous thromboembolism [25–30], myocardial
infarction [31], large-vessel and cardioembolic stroke [32], large-artery arteriosclerosis [33], coronary
artery disease [34,35] and coronary artery disease shared with venous thromboembolism [36]. The
association of these SNPs with thrombosis and with the PFA-100 phenotypes suggests that this
functional platelet test may be useful to estimate thrombotic risk, although further studies are needed
to confirm this. Moreover, some of the SNPs have been described also in association with variations in
VWF, FVIII, and/or variations in biological factors that may play indirect roles in thrombosis, such as
adhesion molecules [17,18,37–39].
Table 2. ABO locus (chromosome 9): SNPs associated with PFA-100 phenotypes which have
been previously described in association with thrombosis-related conditions and with variations
of biological factors.






















0.459 5.21 × 10−14 1.88 × 10−9 VTE [18,25,26,29]
rs687621 136137065 intron 0.432 1.49 × 10−15 3.50 × 10−9




rs687289 136137106 intron 0.433 1.93 × 10−15 5.72 × 10−9 MI [31], LVCES [32]
FVIII [16,17],
ICAM-1 [38]
rs2519093 136141870 intron 0.312 1.16 × 10−12 6.01 × 10−9 VTE [25], LVCES [32] -
rs514659 136142203 intron 0.433 6.04 × 10−15 1.04 × 10−8
VTE [26], MI [31],
LVCES [32], LAA [33] VWF [38]
rs644234 136142217 intron 0.460 1.42 × 10−14 2.18 × 10−9 MI [31], LVCES [32] E-selectin [38]
rs643434 136142355 intron 0.460 1.43 × 10−14 2.18 × 10−9 MI [31], LVCES [32] -
rs545971 136143372 Intron 0.433 6.03 × 10−15 1.04 × 10−8 MI [31], LVCES [32] -
rs612169 136143442 intron 0.433 6.05 × 10−15 1.04 × 10−8 MI [31], LVCES [32]
ICAM-1,
E-selectin [38]
rs674302 136146664 intron 0.433 6.06 × 10−15 1.04 × 10−8 MI [31], LVCES [32] -
rs500498 136148647 intron 0.408 5.56 × 10−08 - VTE [27], LVCES [32]
ICAM-1,
E-selectin [38]
rs505922 136149229 intron 0.433 9.68 × 10−15 1.12 × 10−8
VTE [27,28], MI [31],
LVCES [32] -
rs529565 136149500 intron 0.434 1.86 × 10−14 1.01 × 10−8
VTE [29,30], MI [31],
LVCES [32], LAA [33] -
rs630014 136149722 intron 0.407 8.74 × 10−10 -
VTE [27,28], LVCES
[32] E-selectin [38]
rs651007 136153875 intergenic 0.204 8.02 × 10−12 2.32 × 10−9





rs579459 136154168 intergenic 0.340 3.75 × 10−12 1.35 × 10−9








rs495828 136154867 intergenic 0.340 7.71 × 10−12 2.28 × 10−9
VTE [25,27],
LVCES [32] ACE [38]
rs633862 136155444 intergenic 0.391 2.41 × 10−9 - LVCES [32] -
VTE = venous thromboembolism; MI = myocardial infarction; LVCES = large-vessel and cardioembolic
stroke; LAA = large-artery arteriosclerosis; CAD = coronary artery disease; CAD + VTE = coronary artery
disease shared with venous thromboembolism; VWF = von Willebrand factor; FVIII = coagulant factor VIII;
ACE = angiotensin-converting-enzyme.
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After finding a genetic correlation between the PFA-100 phenotypes and VWF, FVIII and ABO
genotype, we adjusted the GWAS results for these factors. As shown in Figure 2 and Supplementary
Table S1, after adjusting the Col-ADP results for VWF 50, SNPs remained significant but with lower
significance than before adjustment (p-values up to 1.55 × 10−10). After adjusting the Col-ADP, the
results for FVIII 46 SNPs remained significant; almost all were the same as for the VWF adjustment,
but 6 were different. The remaining SNPs also had a lower significance than before (p-values up to
5.00 × 10−11).
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Figure 2. Manhattan plots of the chromosome 9 region of the GWAS on collagen-ADP closure time
phenotype: (A) without adjustments, (B) after adjusting for von Willebrand factor, and (C) after
adjusting for factor VIII. Dots correspond to SNPs organized by position and the vertical axis shows
the statistical significance expressed as -log10 of the p-values. The horizontal lines mark the 5 × 10−8
p-value threshold of genome-wide significance.
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It should be noted that after adjustment of Col-ADP results for ABO genotype, the association
signal disappeared completely (data not shown). Regarding Col-Epi, the significant SNPs disappeared
with any of the adjustments performed, including VWF, FVIII and ABO genotype.
2.3. Genetic Influence of ABO Locus on PFA-100 Phenotypes
Our GWAS results and adjustments suggested that the ABO gene was the main determinant of
variations in PFA-100 CTs since all the significant SNPs associated with PFA-100 phenotypes were at the
ABO locus and all of them lost their genome-wide significance when we adjusted for the ABO genotype.
However, there were differences between Col-ADP and Col-Epi phenotypes. With Col-Epi, all
significant SNPs also disappeared when adjusted for VWF or FVIII. This suggested that the influence
of the ABO gene was related mainly to these factors. Regarding Col-ADP, the adjustment either by
VWF or by FVIII reduced the number of significant SNPs in both cases but 50 and 46 respectively did
not disappear. This suggested that part of the genetic effect of the ABO gene on the Col-ADP was
mediated by VWF and/or FVIII. The relationships among ABO blood group, VWF and FVIII have been
previously described. Non-O group individuals have 25% higher levels of VWF and FVIII than O group
individuals [37,38]. These differences are attributed to the formation of A and B antigens, catalyzed by
specific glucosyltransferases, on the H antigen existing in VWF. They are related to the glycosylation
and clearance rate of VWF which is lower in non-O individuals. We previously showed that FVIII
and VWF were genetically correlated with thrombotic risk, and demonstrated significant linkage
between the ABO locus and plasma levels of VWF and FVIII [40]. More recent GWAS demonstrated
that ABO gene is by far the major determinant of VWF and FVIII levels [18]. This can explain the
genetic relationship between the PFA-100 phenotypes and the ABO blood group through the VWF
and/or FVIII.
According to our results, part of the effect of the ABO locus on the Col-ADP phenotype does
not occur due to WVF and/or FVIII. Some studies have suggested alternative mechanisms by which
the ABO gene can intervene in platelet reactivity, thrombosis, and cardiovascular diseases. Non-O
individuals have higher levels of cholesterol [41]. Also, they have increased amounts of the adhesion
molecules and cytokines involved in inflammation that are related to cardiovascular disease [38,39,42].
Ten of the SNPs that we found at the ABO locus, associated with PFA-100 phenotypes, have been
described previously in association with adhesion molecules and/or cholesterol (Table 2).
Moreover, the ABO blood group can influence platelet reactivity through various mechanisms
related to glycosylation [37,43]. A and B antigens expressed on platelet glycoproteins can modify
the activity of the glycoprotein complexes involved in platelet adhesion and the galectin-glycan
interactions; galectins from extracellular matrices are potent platelet agonists. A and B antigens, also
present on platelet glycosphingolipids, are involved in platelet aggregation and thrombosis by binding
cell adhesion molecules.
Glycosylation is essential also for other platelet functions in which no relationship with the
ABO blood group has been described so far. An example of this is the glycosylation of the P2Y12
receptor [44]. P2Y12 is a Gi-coupled ADP receptor that contains two potential N-linked glycosylation
sites at its extracellular amino-terminus. The lack of glycosylation of this receptor leads to a defective
P2Y12-mediated inhibition of the adenylyl cyclase activity resulting in defective platelet reactivity. The
fact that the effect of the ABO locus, independent of the VWF and/or FVIII, was demonstrated only for
the Col-ADP phenotype gives rise to speculation about the possibility that the ABO locus, among other
mechanisms, could influence the glycosylation of the P2Y12 receptor. Further data are required to
support this hypothesis.
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3. Methods
3.1. Enrollment of Individuals and Families
The enrollment of individuals and families was described in detail in a previous publication [16].
Briefly, 935 individuals from 35 large Spanish families, included in the GAIT-2 Project, were recruited
through a proband with idiopathic thrombophilia and the condition of having at least of 10 members
in at least 3 generations willing to participate in the study. The exclusion criteria were: Deficiencies of
antithrombin, protein S, protein C, heparin cofactor II, or plasminogen, activated protein C resistance,
Factor V Leiden, dysfibrinogenemia, lupus anticoagulant and antiphospholipid antibodies. The
subjects were questioned about their current medication to confirm that they had not taken antiplatelet
drugs in the last two weeks, or other drugs with slight effect on platelet function (such as nonsteroidal
anti-inflammatory drugs or serotonin reuptake inhibitor drugs) in the last week.
Among the individuals studied, 465 were male and 470 were female. The mean age was
39.5 (minimum 2.6, maximum 101, SD 21.4), and 197 of them were 18-years of age or younger.
There were 86 with venous thrombosis, 47 with arterial thrombosis, and 13 with both venous and
arterial thrombosis.
The study was performed according to the Declaration of Helsinki. Written informed consent
was obtained from all adult patients and from parents or guardians of children. All procedures
were approved by the Institutional Review Board at the Hospital de la Santa Creu i Sant Pau. The
GAIT-2 Project was approved on November 23, 2005. At that time, no number was assigned to the
approved projects.
3.2. Blood Collection, Laboratory Analyses and DNA Preparation
Whole blood samples were obtained by venipuncture, under basal conditions, after a 12 h
overnight fast, and between 9:00 a.m. and 9:30 a.m. to minimize the circadian fluctuation. A 5 mL
sample was obtained in EDTA-K3 for determining standard blood cell counts. A 5 mL sample of blood
was collected in 3.8% sodium citrate to be analyzed in the PFA-100 device; the phenotypes obtained
were: CTs (in seconds) for the cartridge collagen-ADP (Col-ADP phenotype) and for the cartridge
collagen-epinephrine (Col-Epi phenotype). To avoid erroneous results due to thrombocytopenia or
anemia, 6 individuals with platelet counts down to 100 × 109/L and 8 individuals with hemoglobin
down to 110 g/L were excluded for the of PFA-100 measurements. Another sample collected in 3.8%
sodium citrate was used to obtain platelet-poor plasma by centrifugation at 2000 g for 20 min at room
temperature. This plasma was used for determining VWF antigen by ELISA and coagulant FVIII
activity as previously described [40]. VWF antigen and coagulant FVIII were recorded as percentages of
an international standard sample. PFA-100 and FVIII activity assays were performed on fresh samples.
DNA was extracted from EDTA blood samples using a standard salting-out procedure [45] or a
commercial kit (Wizard, Promega Corp, Madison, WI, USA). The ABO genotype, that distinguishes the
A1, A2, B, O1 and O2 alleles, was determined as previously described [46]. The primers used were
described in Souto et al. [40].
3.3. Genotyping Filtering and Imputation
We genotyped the samples from 934 individuals, with a combination of
HumanOmniExpressExome-8v1.2 (324 individuals and coverage 964,193 variants) and
HumanCoreExome-12v1.1 (610 individuals and coverage 542,585 variants). After filtering
the datasets by call rate (>98%), Hardy-Weinberg Equilibrium (p-value > 10−6) and minor allele
frequency (MAF) (>1%) and deleting the Mendelian errors, we obtained 395,556 SNPs in all of the
samples. We estimated haplotypes using SHAPEIT v2 [47] and imputed genotypes to the 1000
genomes phase 1 panel using IMPUTE2 [48]. We imputed 37,985,264 SNPs, of which 10,844,567
remained after filtering again by MAF (>0.5%). The 14 individuals who had thrombocytopenia or
anemia were excluded from the association analysis.
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3.4. Statistical Correlation Analyses
The correlations among the phenotypes Col-ADP and Col-Epi with each other and, by pairs, with
other biologically-related phenotypes, were analyzed by multivariate variance component models,
which are an extension of the univariate model [49]. By studying these traits in extended families, we
were able to estimate robustly both the genetic (ρg), and the environmental (ρe) correlations between
pairs of traits.
3.5. GWAS of PFA-100 Phenotypes
We used two phases for the association analysis of normal transformed quantitative phenotypes
with the imputed genotypes. The first was a fast screen of variants with Matrix eQTL [50] using
modelLINEAR. The GWAS of each phenotype was calculated adjusting by age. Sex, smoking and
and oral contraceptives were not included as covariates, since they did not influence the PFA-100 CTs
in the GAIT-2 sample [16]. The “errorCovariance” parameter was used to account for the pedigree
effect. Variants with a p-value < 10−3 were recalculated in the second phase with SOLARIUS [51] and
SOLAR-Eclipse v 8.1.1 [52], using variance component methods. Only the p-values calculated with
SOLAR are reported, since it is considered a gold standard in the field of extended pedigree samples.
SOLAR employs the maximum likelihood approach for variance component models with the standard
likelihood ratio tests to evaluate the statistical significance of the model’s parameters [53].
4. Conclusions
We report the first GWAS on PFA-100 phenotypes. The results of our study suggest that the ABO
locus is the main determinant of these phenotypes and, in the case of Col-Epi, all the ABO influence is
mediated by VWF and/or FVIII. However, for Col-ADP, the influence of ABO is only partially mediated
by VWF and/or FVIII suggesting that other mechanisms may explain the ABO effect on this phenotype.
Much remains to be done to better understand the relationships between ABO blood group and platelet
reactivity measured by PFA-100 test, beyond those mediated by VWF and/or FVIII. Unraveling these
mechanisms will help to identify novel pathways involved in platelet reactivity.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/20/13/3221/s1,
Table S1. Description of the 72 significant SNPs associated with PFA-100 phenotypes: position in the ABO gene
(chromosome 9), location, and significance levels. For collagen-ADP only, the same parameters after adjusting for
von Willebrand factor and for coagulation factor VIII.
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